Decheng Capital

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Medtech Technology is a firm that develops innovative ophthalmic medical devices.It has developed its own artificial lens production and research technology platform, as well as a technological barrier to high-end artificial lens manufacture.

FireFly Bio is a biotechnology company focused on developing innovative therapies for cancer through its proprietary platform centered on Degrader Antibody Conjugates (DACs). This technology merges the advantages of traditional antibody-drug conjugates (ADCs) with selective protein degradation, allowing for the targeted delivery of therapeutic agents to specific tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create highly specific and effective treatments that enhance patient outcomes. The company's approach emphasizes precision in medicine, seeking to improve the potency and efficacy of cancer therapies.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, and innovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.

LEADRIVE is a technology company specializing in the research, development, production, and sales of drive solutions for new energy vehicles, as well as high-performance power semiconductor modules. The company designs and manufactures advanced motor controllers and proprietary power modules that have been adopted by over ten leading automotive manufacturers and Tier-1 suppliers for mass production. LEADRIVE is also engaged in enhancing the localization of power semiconductor modules, with ongoing certification processes for silicon carbide modules and electronic controls. Additionally, the company invests in innovative energy solutions, including wind, solar, and energy storage systems. In collaboration with Rohm Semiconductor from Japan, LEADRIVE has established a joint laboratory to develop various silicon carbide modules, focusing on improving efficiency through comprehensive simulation, testing, and development processes that span from device-level to vehicle-level applications.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, specializes in the development of cell therapies for cancer treatment. The company addresses significant manufacturing challenges associated with these therapies, which are often produced on a per-patient basis, leading to high costs and limited availability. Cellares is pioneering the Cell Shuttle, an automated, closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of ten times more patient doses compared to traditional manual methods, while also reducing process failure rates by three-fold and lowering manufacturing costs by up to 70 percent. By providing flexible and scalable manufacturing options, Cellares aims to accelerate the delivery of life-saving therapies to patients in need and support the broader biopharmaceutical industry in meeting global demand for these treatments.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

VintaBio is a life sciences company that specializes in providing cell and gene therapy manufacturing services to pharmaceutical and biotechnology organizations. The company focuses on addressing the viral vector bottleneck in the development of these therapies by offering customized process development and contract manufacturing solutions. VintaBio possesses extensive industry knowledge and expertise in Good Manufacturing Practices (GMP), supporting clients from proof of concept through clinical trials to biologics license applications. By producing both GMP-grade and research-grade viral vectors, VintaBio enables pharmaceutical companies and molecular biologists to effectively deliver genetic material into cells, thereby facilitating advancements in gene therapy.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

LevitasBio specializes in cellular analytics through its innovative platform that employs magnetic levitation technology. This approach addresses the limitations of traditional cellular analysis by offering label-free and universal methods for studying high-value primary samples and sensitive cell types. The company's LeviCell platform enables scientists to purify cells and nuclei without the need for markers or modifications, allowing for the examination of biological signatures while preserving the integrity of the original samples. By facilitating a deeper and more accurate understanding of biological processes, LevitasBio aims to advance research in the life sciences and healthcare sectors.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, and innovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.

Watchmaker Genomics, Inc. is a biotechnology company based in Boulder, Colorado, specializing in the research and development of genomic technologies. Established in 2018 and formerly known as Alpha Catalyst Genomics, the company focuses on innovative applications for reading, writing, and editing DNA. It leverages extensive expertise in protein engineering and enzyme manufacturing to meet the high standards of quality, performance, and scalability required in the genomics sector. Watchmaker Genomics provides solutions that enhance experimental design, assay efficiency, and workflow processes, offering scalable supply chain solutions that deliver molecular-grade enzymes for various genomic applications.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

Mirvie is a biotechnology company specializing in non-invasive tests for maternal-fetal health, aimed at enhancing the safety of pregnancy. Founded in 2018 by Maneesh Jain and based in South San Francisco, California, Mirvie provides predictive diagnostic tools that deliver actionable insights to expectant mothers and families. Its medical diagnostic platform enables healthcare practitioners to identify at-risk pregnancies, facilitating timely interventions and therapeutic approaches to improve pregnancy outcomes. Through its innovative solutions, Mirvie seeks to empower families with critical information, ensuring a safer pregnancy experience.

USCI Medical Laboratory is a national high-tech company that specializes in genetic testing services, focusing on tumor diagnosis and eugenics gene sequencing solutions. The company is dedicated to developing modern medical health solutions that encompass disease prevention, prediction, detection, interpretation, and intervention. USCI Medical Laboratory excels in batch sample detection and mass data analysis, leveraging advanced gene sequencing technologies and bioinformatics to enhance diagnostic accuracy. It also emphasizes the development of integrated multi-stage diagnostic equipment and clinical processes, providing essential technical and medical support for genomic disease screening and prevention efforts.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Solve Therapeutics is a biopharmaceutical company based in Belmont, California, founded in 2021. The company specializes in the development of first-in-class antibody-drug conjugates and bispecific therapeutics. With a team of experienced professionals, Solve Therapeutics aims to create innovative biopharmaceutical medicines that address significant unmet medical needs, ultimately enhancing patient outcomes and quality of life.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Haoxinqing is an online medical service platform that specializes in mental psychology and chronic disease management. The company offers remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to enhance patient experience and improve health outcomes, making it easier for individuals to manage their mental health and chronic conditions effectively.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

Shape Therapeutics, Inc. is a biotechnology company focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic disorders. Founded in 2018 and headquartered in Seattle, Washington, the company utilizes its proprietary RNAfix technology to edit RNA using the body’s natural cellular machinery. This approach minimizes risks associated with immunogenicity, cellular toxicity, and unintended DNA editing. Shape Therapeutics is dedicated to advancing its innovative platforms for payload, delivery, and manufacturing to enable the development of effective treatments, aiming to address critical health challenges and improve patient outcomes.

GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Xtremity is a medical device company focused on improving the functionality and comfort of prosthetics through innovative socket technology. The company has developed a proprietary product that utilizes advanced polymer materials, allowing for quicker fittings and easy adjustments. This technology is designed to be highly moldable and durable, requiring fewer appointments for users. Xtremity's customizable sockets are compatible with most suspension systems, helping amputees restore their mobility and independence. By prioritizing user experience and adaptability, Xtremity aims to enhance the quality of life for individuals with prosthetic needs.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, specializes in the development of cell therapies for cancer treatment. The company addresses significant manufacturing challenges associated with these therapies, which are often produced on a per-patient basis, leading to high costs and limited availability. Cellares is pioneering the Cell Shuttle, an automated, closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of ten times more patient doses compared to traditional manual methods, while also reducing process failure rates by three-fold and lowering manufacturing costs by up to 70 percent. By providing flexible and scalable manufacturing options, Cellares aims to accelerate the delivery of life-saving therapies to patients in need and support the broader biopharmaceutical industry in meeting global demand for these treatments.

PackGene Biotech is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) based in the United States, specializing in viral vectors for gene therapies. The company excels in developing adeno-associated virus (AAV) vectors, mRNA, plasmid DNA, and lentiviral vector solutions. PackGene Biotech offers comprehensive services from vector design and construction to AAV, lentivirus, and mRNA production. With a focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, the company provides cost-effective, reliable, and scalable production solutions for medical industry researchers.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

EpimAb Biotherapeutics is a privately held biopharmaceutical company based in Shanghai that develops novel bispecific antibody therapeutics, with a focus on immuno-oncology and other high-value indications. The company uses its proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform to generate bispecific molecules that combine antibody-like properties with improved design features, aiming to enhance target binding, pharmacokinetics and manufacturability. Through in-house research and development, EpimAb advances novel bispecific candidates intended to expand treatment options for patients and address remaining challenges in bispecific drug development.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and immuno-inflammatory disorders with high unmet medical need. Its lead candidate, EQ001 (Itolizumab), is a first-in-class monoclonal antibody that selectively targets the CD6 immune receptor to downregulate pathogenic effector T cells while preserving regulatory T cells by modulating the CD6-ALCAM signaling pathway. The approach targets a range of immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. Equillium aims to advance its programs through clinical development and may commercialize products independently or through partnerships or strategic transactions to monetize its pipeline.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

LevitasBio specializes in cellular analytics through its innovative platform that employs magnetic levitation technology. This approach addresses the limitations of traditional cellular analysis by offering label-free and universal methods for studying high-value primary samples and sensitive cell types. The company's LeviCell platform enables scientists to purify cells and nuclei without the need for markers or modifications, allowing for the examination of biological signatures while preserving the integrity of the original samples. By facilitating a deeper and more accurate understanding of biological processes, LevitasBio aims to advance research in the life sciences and healthcare sectors.

Encodia, Inc. is a biotechnology company based in San Diego, California, founded in 2015. The company specializes in proteomics research, providing innovative solutions for protein analysis through its proprietary technology. Encodia's platform utilizes a novel reverse-translation process that converts peptide sequence information into a DNA library, facilitating scalable and efficient protein sequencing. This technology allows researchers to gain comprehensive insights into cellular processes, thereby advancing personalized medicine and accelerating the discovery of novel approaches to address complex diseases. By democratizing protein sequencing, Encodia aims to enhance the capabilities of scientists in their pursuit of understanding the proteome.

GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

PackGene Biotech is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) based in the United States, specializing in viral vectors for gene therapies. The company excels in developing adeno-associated virus (AAV) vectors, mRNA, plasmid DNA, and lentiviral vector solutions. PackGene Biotech offers comprehensive services from vector design and construction to AAV, lentivirus, and mRNA production. With a focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, the company provides cost-effective, reliable, and scalable production solutions for medical industry researchers.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Everest Medicines Limited is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017. The company is focused on licensing, developing, and commercializing innovative therapies aimed at addressing significant unmet medical needs primarily in Greater China and other Asia Pacific markets. Its portfolio includes eight clinical-stage drug candidates targeting various conditions, including oncology, immunology, cardio-renal disease, and infectious diseases. By integrating discovery, clinical development, commercialization, and manufacturing processes, Everest Medicines seeks to deliver potentially transformative pharmaceutical therapies that improve patient outcomes. The company aims to partner with leading global pharmaceutical firms to bring its products to market, leveraging its team's expertise in clinical development, regulatory affairs, and operations.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing antibody therapeutics for cancer treatment. Established in 2010, Apexigen specializes in immuno-oncology, creating therapies that aim to leverage the patient's immune system to effectively combat and eradicate cancer. The company's pipeline includes several promising candidates, such as APX005M and APX201 for immuno-oncology, along with additional programs targeting various oncology and inflammation conditions. Notably, its lead candidate, sotigalimab, is currently in clinical development, complemented by a range of preclinical immuno-oncology programs. Apexigen also utilizes its proprietary APXiMAB platform to discover novel antibodies targeting immune system pathways, underscoring its commitment to advancing innovative treatments in cancer care.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

ReadCoor, Inc. is a technology company based in Cambridge, Massachusetts, specializing in the development and commercialization of a panomic spatial sequencing platform. The company offers the RC2 Platform, which utilizes proprietary Fluorescent in situ Sequencing (FISSEQ) technology to enable researchers, clinicians, and pharmaceutical and diagnostics companies to perform multi-omic analyses. This platform allows for the simultaneous detection and sequencing of numerous RNA, DNA, proteins, and therapeutics while visualizing sub-cellular nanoscale 3D resolution across tissue sections. By integrating high throughput sequencing with morphometric analysis and three-dimensional spatial imaging, ReadCoor provides valuable insights into human biology, facilitating the development of new therapeutics for various conditions, including cancer, infectious diseases, and neurological disorders. Founded in 2016, ReadCoor operates as a subsidiary of 10x Genomics, Inc. as of October 2020.

Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.

KeChow Pharma, established in 2014 and headquartered in Shanghai, China, is a biopharmaceutical company specializing in novel drug discovery. It concentrates on developing targeted small molecule drugs as alternatives to existing therapies, collaborating with partners for co-development.

Mynosys Cellular Devices is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enable procedural excellence

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Hummingbird Bioscience is a biotechnology company specializing in the development of novel therapeutic antibodies for oncology and immuno-oncology indications. Utilizing systems biology approaches and proprietary computational platforms, they discover and engineer innovative biotherapeutics targeting challenging disease pathways with strong biological validation. Their pipeline includes lead assets HMBD-001 (anti-HER3) and HMBD-002 (anti-VISTA), both in cancer treatment. The company has formed strategic partnerships with Cancer Research UK and Amgen, and received a product development grant from the Cancer Prevention and Research Institute of Texas.

AnHeart Therapeutics is a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of innovative pharmaceutical products. The company focuses on acquiring, developing, and commercializing novel therapies that enhance human health and quality of life. Its primary research product, AB-106, is an oral, highly selective small molecule inhibitor targeting ROS1 and NTRK, aimed at providing precision treatment options for individuals with cancer. Through its pipeline of advanced therapies, AnHeart Therapeutics seeks to enable medical professionals to deliver effective solutions that address critical needs in oncology.

Baoyuan Biomedical is a clinical stage company focused on acquiring, developing and commercializing innovative drugs that improve human health and quality of life, and is committed to innovative drug development that does not meet clinical needs. Its main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Luckin Coffee Inc. is a prominent coffee retailer based in Xiamen, China, specializing in the sale of freshly brewed drinks and pre-made food items. Founded in 2017, the company aims to establish itself as a leading high-quality coffee brand and professional coffee service provider in the country. It offers a diverse range of products, including coffee and non-coffee beverages, alongside light meals. The company operates through various store formats, including pick-up stores, relax stores, and delivery kitchens, and utilizes a mobile app and third-party platforms to facilitate customer purchases. By sourcing premium Arabica coffee beans and collaborating with World Barista Champion teams for recipe development, Luckin Coffee strives to enhance the coffee consumer experience and promote coffee culture in China. As of March 2019, it operated 2,370 stores across 28 cities in the country.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company is advancing a pipeline of therapeutics, including TERN-101, a potent non-bile acid farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. Terns leverages its expertise in disease biology and medicinal chemistry, along with a cost-effective drug discovery model and robust clinical development capabilities, to create innovative therapies that address significant unmet medical needs both in China and globally.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing antibody therapeutics for cancer treatment. Established in 2010, Apexigen specializes in immuno-oncology, creating therapies that aim to leverage the patient's immune system to effectively combat and eradicate cancer. The company's pipeline includes several promising candidates, such as APX005M and APX201 for immuno-oncology, along with additional programs targeting various oncology and inflammation conditions. Notably, its lead candidate, sotigalimab, is currently in clinical development, complemented by a range of preclinical immuno-oncology programs. Apexigen also utilizes its proprietary APXiMAB platform to discover novel antibodies targeting immune system pathways, underscoring its commitment to advancing innovative treatments in cancer care.

IMPACT Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009 and based in Shanghai, China, the company focuses on creating targeted anti-cancer treatments utilizing synthetic lethality. IMPACT Therapeutics is actively engaged in several research and development projects, including a PARP inhibitor, a Wee1 inhibitor, and various novel agents targeting DNA damage response mechanisms and the Hedgehog signaling pathway. Through its commitment to advancing treatment options, IMPACT Therapeutics aims to provide patients with effective and targeted anti-cancer therapies.

Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.

Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

Mindstrong Health, established in 2013 and based in Mountain View, California, specializes in remote mental health care. It offers a digital therapeutic platform that combines AI-powered technology, data, and clinical expertise to monitor and improve users' mental health. The platform tracks symptoms continuously through passive data collection from human-computer interactions, enabling evidence-based interventions and personalized support. Services include cognitive behavioral therapy, psychoeducation, crisis management, and more, helping thousands of users, including those with serious mental illness.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

LevitasBio specializes in cellular analytics through its innovative platform that employs magnetic levitation technology. This approach addresses the limitations of traditional cellular analysis by offering label-free and universal methods for studying high-value primary samples and sensitive cell types. The company's LeviCell platform enables scientists to purify cells and nuclei without the need for markers or modifications, allowing for the examination of biological signatures while preserving the integrity of the original samples. By facilitating a deeper and more accurate understanding of biological processes, LevitasBio aims to advance research in the life sciences and healthcare sectors.

BCFoods is a food processing company that produces condiments, tomato paste, and other food ingredients from dehydrated fruits and vegetables. The company built an agricultural demonstration base to plant onion, tomato, and pepper crops and produce major types of vegetable and fruit pastes.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

EpimAb Biotherapeutics is a privately held biopharmaceutical company based in Shanghai that develops novel bispecific antibody therapeutics, with a focus on immuno-oncology and other high-value indications. The company uses its proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform to generate bispecific molecules that combine antibody-like properties with improved design features, aiming to enhance target binding, pharmacokinetics and manufacturability. Through in-house research and development, EpimAb advances novel bispecific candidates intended to expand treatment options for patients and address remaining challenges in bispecific drug development.

Cirina is a biotechnology company based in South San Francisco, California, focused on developing innovative blood-plasma tests to detect deadly diseases, particularly cancer, at their earliest stages. Founded by Dennis Lo, a pioneer in plasma nucleic acid research, Cirina aims to leverage groundbreaking science to empower patients in taking preventive actions against diseases when curative treatments are most effective. The company is actively seeking to attract top scientific and business talent to enhance its mission of early disease detection and monitoring, thereby improving patient outcomes and healthcare strategies.

ReadCoor, Inc. is a technology company based in Cambridge, Massachusetts, specializing in the development and commercialization of a panomic spatial sequencing platform. The company offers the RC2 Platform, which utilizes proprietary Fluorescent in situ Sequencing (FISSEQ) technology to enable researchers, clinicians, and pharmaceutical and diagnostics companies to perform multi-omic analyses. This platform allows for the simultaneous detection and sequencing of numerous RNA, DNA, proteins, and therapeutics while visualizing sub-cellular nanoscale 3D resolution across tissue sections. By integrating high throughput sequencing with morphometric analysis and three-dimensional spatial imaging, ReadCoor provides valuable insights into human biology, facilitating the development of new therapeutics for various conditions, including cancer, infectious diseases, and neurological disorders. Founded in 2016, ReadCoor operates as a subsidiary of 10x Genomics, Inc. as of October 2020.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a 40mm pre-tied suture loop for effective soft tissue closure through minimally invasive access points as small as 4.3mm. This innovative technology eliminates the need for metal, clips, or fabrics, ensuring a complete and immediate closure without leaving foreign materials in the body. SentreHEART has received regulatory clearance for its device for soft tissue ligation and approximation in the United States, Europe, and Canada, enhancing surgical options and patient safety by reducing the risk of thromboembolism.

BCFoods is a food processing company that produces condiments, tomato paste, and other food ingredients from dehydrated fruits and vegetables. The company built an agricultural demonstration base to plant onion, tomato, and pepper crops and produce major types of vegetable and fruit pastes.

AccuraGen Inc. is a biotechnology company based in Menlo Park, California, that specializes in sequencing-based cancer-mutation detection systems. Established in 2013, AccuraGen has developed a high-sensitivity technology that detects cancer mutations present in minuscule amounts of circulating cell-free DNA (cfDNA) found in blood samples. This innovative approach addresses significant challenges associated with utilizing information from cfDNA by employing proprietary molecular biology techniques and computational algorithms to minimize errors. The company's technology enables the amplification of nanogram quantities of fragmented cfDNA over 1000-fold, allowing for the screening of tens to hundreds of cancer-related genes with single-digit molecular sensitivity. AccuraGen aims to support personalized cancer treatment by providing valuable molecular diagnostic information to oncologists and clinicians.

GeneWeave Biosciences specializes in developing advanced diagnostic solutions to enhance clinical microbiology and address the challenges posed by drug-resistant infections. The company aims to support hospitals and physicians globally by enabling improved antibiotic stewardship and providing rapid determinations of optimal antibiotic therapy for critical bacterial infections. Utilizing its proprietary Smarticles™ technology, GeneWeave delivers homogeneous assays that can quickly measure bacterial drug resistance without the need for enrichment, culture, or extensive sample preparation, thereby streamlining the diagnostic process and contributing to better patient outcomes.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

GeneWeave Biosciences specializes in developing advanced diagnostic solutions to enhance clinical microbiology and address the challenges posed by drug-resistant infections. The company aims to support hospitals and physicians globally by enabling improved antibiotic stewardship and providing rapid determinations of optimal antibiotic therapy for critical bacterial infections. Utilizing its proprietary Smarticles™ technology, GeneWeave delivers homogeneous assays that can quickly measure bacterial drug resistance without the need for enrichment, culture, or extensive sample preparation, thereby streamlining the diagnostic process and contributing to better patient outcomes.